Chemours Co (NYSE:CC) Shares Purchased by Delta Investment Management LLC

Delta Investment Management LLC boosted its holdings in Chemours Co (NYSE:CC) by 54.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 18,049 shares of the specialty chemicals company’s stock after buying an additional 6,369 shares during the quarter. Delta Investment Management LLC’s holdings in Chemours were worth $269,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Third Point LLC increased its stake in Chemours by 118.8% in the second quarter. Third Point LLC now owns 4,375,000 shares of the specialty chemicals company’s stock valued at $105,000,000 after purchasing an additional 2,375,000 shares during the last quarter. LSV Asset Management increased its stake in Chemours by 4.5% in the second quarter. LSV Asset Management now owns 3,860,806 shares of the specialty chemicals company’s stock valued at $92,659,000 after purchasing an additional 165,800 shares during the last quarter. Invesco Ltd. increased its stake in Chemours by 171.4% in the second quarter. Invesco Ltd. now owns 2,466,635 shares of the specialty chemicals company’s stock valued at $59,199,000 after purchasing an additional 1,557,746 shares during the last quarter. M&T Bank Corp increased its stake in Chemours by 71.6% in the second quarter. M&T Bank Corp now owns 1,158,451 shares of the specialty chemicals company’s stock valued at $27,803,000 after purchasing an additional 483,539 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Chemours by 7.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 1,088,495 shares of the specialty chemicals company’s stock worth $26,124,000 after acquiring an additional 74,964 shares during the last quarter. Hedge funds and other institutional investors own 79.88% of the company’s stock.

Shares of NYSE:CC opened at $19.69 on Friday. The firm has a market capitalization of $3.23 billion, a PE ratio of 3.47, a P/E/G ratio of 0.51 and a beta of 2.57. The company has a debt-to-equity ratio of 5.05, a current ratio of 1.72 and a quick ratio of 1.09. The business has a 50-day moving average of $15.60 and a two-hundred day moving average of $19.81. Chemours Co has a 12 month low of $11.71 and a 12 month high of $41.60.

Chemours (NYSE:CC) last posted its earnings results on Monday, November 4th. The specialty chemicals company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. Chemours had a return on equity of 58.38% and a net margin of 7.24%. The business had revenue of $1.39 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter last year, the firm earned $1.49 earnings per share. The company’s revenue for the quarter was down 14.6% compared to the same quarter last year. As a group, research analysts anticipate that Chemours Co will post 2.44 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be paid a $0.25 dividend. The ex-dividend date is Thursday, November 14th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 5.08%. Chemours’s dividend payout ratio (DPR) is currently 17.64%.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In related news, COO Mark Newman bought 20,000 shares of the stock in a transaction dated Wednesday, September 11th. The stock was acquired at an average price of $16.42 per share, for a total transaction of $328,400.00. Following the completion of the purchase, the chief operating officer now owns 114,261 shares in the company, valued at $1,876,165.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.34% of the stock is currently owned by company insiders.

Several equities research analysts have commented on CC shares. Argus lowered Chemours from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. ValuEngine lowered Chemours from a “hold” rating to a “sell” rating in a research note on Friday, November 1st. Citigroup upped their price target on Chemours from $14.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday. Royal Bank of Canada lowered Chemours from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $32.00 to $16.00 in a research note on Friday, August 9th. Finally, UBS Group dropped their price target on Chemours from $19.00 to $14.50 and set a “neutral” rating for the company in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $27.14.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Further Reading: What are the benefits of a balanced fund?

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Co (NYSE:CC).

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Leave a Reply

Your email address will not be published. Required fields are marked *

*